Merck received FDA approval for Keytruda plus chemotherapy for some patients with advanced esophageal or gastroesophageal junction cancer.
Adding Herceptin to chemotherapy improved outcomes for patients with HER2-positive advanced gastric cancer in a clinical trial.
The targeted drug Cyramza combined with chemotherapy produced a disease-control rate of 81% in a trial of previously treated gastric cancer patients.
Chemotherapy after surgery for gastric cancer was superior to chemoradiation in a recent trial.
Five Prime Therapeutics’ FGFR2b-targeted drug combined with chemotherapy improved survival in a phase 2 trial.